share_log

LifeSci Capital Initiates Coverage On Mereo BioPharma Group With Outperform Rating, Announces Price Target of $10

LifeSci Capital Initiates Coverage On Mereo BioPharma Group With Outperform Rating, Announces Price Target of $10

LifeSci Capital對Mereo BioPharma Group發起覆蓋,給予優於大盤評級,並宣佈目標價爲10美元。
Benzinga ·  12/24 19:06  · 評級/大行評級

LifeSci Capital analyst Cory Jubinville initiates coverage on Mereo BioPharma Group (NASDAQ:MREO) with a Outperform rating and announces Price Target of $10.

LifeSci Capital 分析師Cory Jubinville對Mereo BioPharma Group (納斯達克:MREO)的覆蓋評級爲跑贏大盤,並宣佈價格目標爲10美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論